Treating organoids with SFAs and observing the activation of NF-κB and subsequent changes in cell behavior (such as proliferation, apoptosis, and differentiation) can help understand the impact of SFAs on the tumor microenvironment and the progression of prostate cancer. The gene discussed is NFKB1; the disease is prostate cancer.